Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gpASIT+ in Grass Pollen-induced Allergic Rhinoconjunctivitis
NCT02560948Phase 3Completed
- Sponsor
- TOOLS Life Science
- Start
- Dec 2015
- Primary completion
- Aug 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of gpASIT+ in allergic rhinoconjunctivitis (ARC), sponsored by TOOLS Life Science. Started Dec 2015; status: completed.
02
Drugs
gpASIT+
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02560948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560948.